CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionGross margin is 4.6%, lower than 95% of its Biotechnology peers (median 67.2%)
- FinancialsAltman Z-Score -1.08: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
525.32MEUR596.91M · vs all stocks (USD)
Revenue (TTM)
142.94MEUR162.42M · vs all stocks (USD)
Profit Margin
-110.29%vs Biotechnology peers
Beta
1.37xvs all stocks
52-Week Change
-43.86%vs all stocks
Market Capitalization
525.32MEUR596.91M · vs all stocks (USD)
Enterprise Value
593.17MEUR674.00M · vs all stocks (USD)
Forward P/E
17.27xvs Biotechnology peers
Price to Sales (TTM)
3.53xvs Biotechnology peers
Price to Book (MRQ)
6.21xvs Biotechnology peers
Enterprise to Revenue
4.15xvs Biotechnology peers
Enterprise to EBITDA
-6.01xvs Biotechnology peers
Gross Margin
4.58%vs Biotechnology peers
Profit Margin
-110.29%vs Biotechnology peers
Operating Margin
-74.92%vs Biotechnology peers
Return on Assets (TTM)
-16.68%vs Biotechnology peers
Return on Equity (TTM)
-117.85%vs Biotechnology peers
Revenue (TTM)
142.94MEUR162.42M · vs all stocks (USD)
Revenue per Share (TTM)
0.8010EURUpdated Sep 29, 2026Quarterly Revenue Growth
-27.70%vs Biotechnology peers
Gross Profit (TTM)
-59.65MEUR-67.78M · vs all stocks (USD)
EBITDA (TTM)
-98.72MEUR-112.17M · vs all stocks (USD)
Net Income (TTM)
-157.65MEUR-179.13M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-27.71%vs Biotechnology peers
Operating Cash Flow (TTM)
-55.69MEUR-63.28M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-42.50MEUR-48.29M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00EURUpdated Sep 29, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
174.66MEURFY2025 · Dec 31, 2025Cost of Goods Sold
107.14MEURFY2025 · Dec 31, 2025Gross Profit
67.52MEURFY2025 · Dec 31, 2025Operating Income
-81.63MEUR-92.76M · vs all stocks (USD)
Pre-tax Income
-114.12MEURFY2025 · Dec 31, 2025Income Tax Expense
1.07MEURFY2025 · Dec 31, 2025Net Income
-115.19MEURFY2025 · Dec 31, 2025EBIT
-72.22MEURFY2025 · Dec 31, 2025EBITDA (Income Statement)
-57.24MEURFY2025 · Dec 31, 2025Research & Development
85.30MEURFY2025 · Dec 31, 2025Selling, General & Administrative
74.68MEURFY2025 · Dec 31, 2025Other Operating Expenses
-11.20MEURFY2025 · Dec 31, 2025Non-operating Interest Income
1.80MEURFY2025 · Dec 31, 2025Non-operating Interest Expense
41.90MEURFY2025 · Dec 31, 2025EPS (Basic)
-0.6800EURFY2025 · Dec 31, 2025EPS (Diluted)
-0.6800EURFY2025 · Dec 31, 2025Basic Shares Outstanding
168.18MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
168.18MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-115.19MEURFY2025 · Dec 31, 2025Operating Cash Flow
-48.13MEURFY2025 · Dec 31, 2025Free Cash Flow
-52.42MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
109.65MEURFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-115.19MEURFY2025 · Dec 31, 2025Depreciation & Amortization
21.75MEURFY2025 · Dec 31, 2025Deferred Taxes (CF)
1.07MEURFY2025 · Dec 31, 2025Stock-based Compensation
9.53MEURFY2025 · Dec 31, 2025Other Non-cash Items
30.40MEURFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
13.33MEURFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-9.02MEURFY2025 · Dec 31, 2025Capital Expenditures
-4.29MEURFY2025 · Dec 31, 2025Net Intangibles (CF)
-61.00KEURFY2025 · Dec 31, 2025Net Acquisitions
0.00EURFY2025 · Dec 31, 2025Sale of Investments
841.00KEURFY2025 · Dec 31, 2025Net Investing Cash Flow
-3.45MEURFY2025 · Dec 31, 2025Long-term Debt Issuance
174.40MEURFY2025 · Dec 31, 2025Long-term Debt Payments
-174.34MEURFY2025 · Dec 31, 2025Common Dividends Paid
0.00EURFY2025 · Dec 31, 2025Other Financing Charges
1.00KEURFY2025 · Dec 31, 2025Net Financing Cash Flow
62.00KEURFY2025 · Dec 31, 2025Shares Outstanding
204.24MSharesUpdated Sep 29, 2026Float Shares
157.26MSharesUpdated Sep 29, 2026% Held by Insiders
10.72%vs all stocks
% Held by Institutions
23.88%vs all stocks
Total Cash (MRQ)
121.53MEUR138.09M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.6410EURUpdated Sep 29, 2026Total Debt (MRQ)
210.23MEUR238.88M · vs all stocks (USD)
Total Debt to Equity (MRQ)
2.59xvs Biotechnology peers
Current Ratio (MRQ)
2.16xvs Biotechnology peers
Book Value per Share (MRQ)
0.4280EURUpdated Sep 29, 2026Total Assets
398.84MEUR453.19M · vs all stocks (USD)
Total Current Assets
222.54MEURFY2025 · Dec 31, 2025Total Liabilities
292.67MEURFY2025 · Dec 31, 2025Total Non-current Assets
176.30MEURFY2025 · Dec 31, 2025Total Non-current Liabilities
199.33MEURFY2025 · Dec 31, 2025Total Current Liabilities
93.33MEURFY2025 · Dec 31, 2025Cash
109.65MEURFY2025 · Dec 31, 2025Cash & Cash Equivalents
109.65MEURFY2025 · Dec 31, 2025Accounts Receivable
27.73MEURFY2025 · Dec 31, 2025Inventory
50.23MEURFY2025 · Dec 31, 2025Accounts Payable
9.07MEURFY2025 · Dec 31, 2025Short-term Debt
20.64MEURFY2025 · Dec 31, 2025Deferred Revenue
432.00KEURFY2025 · Dec 31, 2025Other Current Liabilities
5.69MEURFY2025 · Dec 31, 2025Long-term Debt
186.60MEURFY2025 · Dec 31, 2025Other Non-current Liabilities
245.00KEURFY2025 · Dec 31, 2025Common Stock (Book)
26.03MEURFY2025 · Dec 31, 2025Retained Earnings
-679.12MEURFY2025 · Dec 31, 2025Total Shareholders' Equity
106.17MEUR120.64M · vs all stocks (USD)
Treasury Stock
645.00KEURFY2025 · Dec 31, 202552-Week Low
2.03EURUpdated Sep 29, 202652-Week High
5.33EURUpdated Sep 29, 202652-Week Change
-43.86%vs all stocks
Beta
1.37xvs all stocks
50-Day MA
2.63EURUpdated Sep 29, 2026200-Day MA
3.09EURUpdated Sep 29, 2026Avg 10-Day Volume
288.08KSharesUpdated Sep 29, 2026Avg 30-Day Volume
848.77KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
-0.9000EURUpdated Sep 29, 2026Other Income / Expense
6.76MEURFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 4.6%, lower than 95% of its Biotechnology peers (median 67.2%)Significant
Gross margin: 0.05Industry median: 0.67Industry P5: 0.14Peers compared: 260
Debt-to-equity is 2.59×, higher than 95% of its Biotechnology peers (median 0.07×)Significant
Debt-to-equity: 2.59Industry median: 0.07Industry P95: 0.93Peers compared: 260
Structural Tensions
Significant cash reserves alongside high leverageNotable
Cash (USD): 138,087,563.28Total Debt (USD): 238,881,289.77Debt-to-Equity: 2.59
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.16Altman Z-Score: -1.08
Financial Health
Altman Z-Score -1.08: distress zoneCritical
Altman Z-Score: -1.08
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genfit S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jinling Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hefei Lifeon Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Gkht Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Miracure Pharmaceuticals Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Surrozen, Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
JFrog Ltd.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Fastly Inc.
1 interpretationHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC